Frazier Life Sciences Management’s BridgeBio Pharma BBIO Stock Holding History

Frazier Life Sciences Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115M	Sell	1,548,139 -1,900,000	-55%	-$133M	2.51%	11
2026 Q1	$256M	Sell	3,448,139 -97,418	-3%	-$7.06M	6.59%	4
2025 Q4	$271M	Sell	3,545,557 -299,900	-8%	-$19.7M	7.28%	4
2025 Q3	$200M	Buy	3,845,457 +45,000	+1%	+$2.19M	5.98%	4
2025 Q2	$164M	Hold	3,800,457	–	–	6.56%	4
2025 Q1	$131M	Hold	3,800,457	–	–	6%	5
2024 Q4	$104M	Buy	3,800,457 +40,000	+1%	+$1.03M	4.33%	9
2024 Q3	$95.7M	Buy	3,760,457 +127,853	+4%	+$3.36M	3.84%	9
2024 Q2	$92M	Buy	3,632,604 +217,000	+6%	+$5.93M	4.3%	7
2024 Q1	$106M	Buy	3,415,604 +689,655	+25%	+$23.5M	4.46%	7
2023 Q4	$110M	Hold	2,725,949	–	–	5.88%	5
2023 Q3	$71.9M	Buy	2,725,949 +737,073	+37%	+$20.9M	4.77%	6
2023 Q2	$34.2M	Buy	1,988,876 +817,226	+70%	+$12.3M	2.04%	12
2023 Q1	$19.4M	Buy	+1,171,650	New	+$13.7M	1.41%	20

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Frazier Life Sciences Management's BBIO Position: Q2 2026 in Review

Frazier Life Sciences Management reduced its BridgeBio Pharma (BBIO) stake by 55% in Q2 2026, selling an estimated $133M and leaving 1,548,139 shares worth $115M. The position accounts for 2.51% of the portfolio, ranked #11.

Frazier Life Sciences Management first reported a position in BBIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $271M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Frazier Life Sciences Management held 1,548,139 shares of BridgeBio Pharma worth $115M as of Q2 2026.
Frazier Life Sciences Management sold 1,900,000 BridgeBio Pharma shares in Q2 2026, an estimated $133M.
BridgeBio Pharma made up 2.51% of Frazier Life Sciences Management's portfolio in Q2 2026, its #11 holding.
Frazier Life Sciences Management first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 14 quarters since.
Frazier Life Sciences Management's BridgeBio Pharma position peaked at $271M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.